0000885590-12-000080.txt : 20121213
0000885590-12-000080.hdr.sgml : 20121213
20121213161736
ACCESSION NUMBER: 0000885590-12-000080
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20121211
FILED AS OF DATE: 20121213
DATE AS OF CHANGE: 20121213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hanson Jason David
CENTRAL INDEX KEY: 0001368586
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 121262310
MAIL ADDRESS:
STREET 1: 8125 NORTH HAYDEN ROAD
CITY: SCOTTSDALE
STATE: AZ
ZIP: 85258-2463
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4787 LEVY STREET
STREET 2: MONTREAL
CITY: QUEBEC
STATE: A8
ZIP: H4R 2P9
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 4787 LEVY STREET
STREET 2: MONTREAL
CITY: QUEBEC
STATE: A8
ZIP: H4R 2P9
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2012-12-11
0
0000885590
Valeant Pharmaceuticals International, Inc.
VRX
0001368586
Hanson Jason David
4787 LEVY STREET
MONTREAL
A8
H4R 2P9
QUEBEC, CANADA
0
1
0
0
EVP, Company Group Chairman
Non-Qualified Stock (right to purchase)
58.16
2012-12-11
4
A
0
84500
0
A
2016-12-11
2022-12-11
Common Shares, no par value
84500
84500
D
Restricted Share Units
0
2012-12-11
4
A
0
36300
0
A
Common Shares, no par value
36300
36300
D
The options vest 25% per year for 4 years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant and the fourth vest date falling on the fourth anniversary of the grant.
Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (3).
The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $55.66 on each of three measurement dates: 25% would vest on September 11, 2015, 50% on December 11, 2015 and 25% on March 11, 2016, with early vesting possible at higher TSR levels.
by: Nicholas Zanoni for Jason D. Hanson
2012-12-13